Embecta Shares Gain As Q1 Earnings Exceed Expectations
Embecta Corp (NASDAQ:EMBC) posted Q1 FY23 revenues of $275.7 million, down 4.7% on a reported basis and up 0.7% on…
InMode’s Q4 Earnings Surpass Expectations, Issues Mixed FY23 Guidance
InMode Ltd (NASDAQ:INMD) has reported Q4 sales of $133.6 million, +21% Y/Y, beating the consensus of $129.14 million. The company…
Credit Suisse Warns Former Staff Copied Personnel And Salary Data
Credit Suisse Group AG (NYSE: CS) says a former staffer with legitimate access to data, copied some of its workforce's data several years ago, including descriptions of their compensation.
US Federal Judge Rejects Victim Families Push To Nullify Boeing Deal Over Max Crashes
A federal judge rejected a challenge by relatives of Boeing Co's (NYSE: BA) 737 MAX crash victims to reopen or reject a 2021 deferred prosecution agreement between Boeing and the U.S. Department of Justice (DoJ).
Barron’s Top Weekend Stock Picks: Google, Microsoft, Disney And Is Elon Musk Set To Become World’s Richest Person Again?
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Benzinga Bulls And Bears: Apple, Disney, Berkshire Hathaway And Why Kevin O’Leary Says 10,000 Cryptos Will Be Worthless
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Bristol-Myers Squibb & Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) announced the first publication and presentation of results from the KarMMa-3 Phase 3 study…
Oil Stocks Jump After Russia Responds To Western Sanctions: What You Need To Know
Oil prices climbed Friday after Russia announced a voluntary production cut of 500,000 barrels per day in March in response to Western price caps.
New Data Shows Roche’s Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Roche Holdings AG (OTC:RHHBY) announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab) in macular…
Analysts Says Azenta Could See Recovery, Stock Likely Rangebound
Azenta Inc (NASDAQ:AZTA) reported a Q1 EPS of $0.12, beating the consensus of $0.08. Sales increased 28% Y/Y to $178.37…